{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:49:59Z","timestamp":1792601399612,"version":"4.5.0"},"reference-count":98,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:00:00Z","timestamp":1707782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>(1) Background: Osteogenesis imperfecta (OI) is a rare skeletal dysplasia characterized as a heterogeneous disorder group with well-defined phenotypic and genetic features that share uncommon bone fragility. The current treatment options, medical and orthopedic, are limited and not efficient enough to improve the low bone density, bone fragility, growth, and mobility of the affected individuals, creating the need for alternative therapeutic agents. (2) Methods: We searched the medical database to find papers regarding treatments for OI other than conventional ones. We included 45 publications. (3) Results: In reviewing the literature, eight new potential therapies for OI were identified, proving promising results in cells and animal models or in human practice, but further research is still needed. Bone marrow transplantation is a promising therapy in mice, adults, and children, decreasing the fracture rate with a beneficial effect on structural bone proprieties. Anti-RANKL antibodies generated controversial results related to the therapy schedule, from no change in the fracture rate to improvement in the bone mineral density resorption markers and bone formation, but with adverse effects related to hypercalcemia. Sclerostin inhibitors in murine models demonstrated an increase in the bone formation rate and trabecular cortical bone mass, and a few human studies showed an increase in biomarkers and BMD and the downregulation of resorption markers. Recombinant human parathormone and TGF-\u03b2 generated good results in human studies by increasing BMD, depending on the type of OI. Gene therapy, 4-phenylbutiric acid, and inhibition of eIF2\u03b1 phosphatase enzymes have only been studied in cell cultures and animal models, with promising results. (4) Conclusions: This paper focuses on eight potential therapies for OI, but there is not yet enough data for a new, generally accepted treatment. Most of them showed promising results, but further research is needed, especially in the pediatric field.<\/jats:p>","DOI":"10.3390\/jcm13041065","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T04:18:22Z","timestamp":1707884302000},"page":"1065","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["New Perspectives of Therapies in Osteogenesis Imperfecta\u2014A Literature Review"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8008-4408","authenticated-orcid":false,"given":"Alexandru","family":"Dinulescu","sequence":"first","affiliation":[{"name":"Departament of Pediatrics and Department of Pediatric Orthopedics, \u201cCarol Davila\u201c University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Departament of Pediatrics and Department of Pediatric Orthopedics, Emergency Hospital for Children \u2018\u2019Grigore Alexandrescu\u2019\u2019, 011743 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru-Sorin","family":"P\u0103s\u0103ric\u0103","sequence":"additional","affiliation":[{"name":"Departament of Pediatrics and Department of Pediatric Orthopedics, Emergency Hospital for Children \u2018\u2019Grigore Alexandrescu\u2019\u2019, 011743 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u0103d\u0103lina","family":"Carp","sequence":"additional","affiliation":[{"name":"Departament of Pediatrics and Department of Pediatric Orthopedics, \u201cCarol Davila\u201c University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Departament of Pediatrics and Department of Pediatric Orthopedics, Emergency Hospital for Children \u2018\u2019Grigore Alexandrescu\u2019\u2019, 011743 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Du\u0219c\u0103","sequence":"additional","affiliation":[{"name":"Departament of Pediatrics and Department of Pediatric Orthopedics, \u201cCarol Davila\u201c University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Departament of Pediatrics and Department of Pediatric Orthopedics, Emergency Hospital for Children \u2018\u2019Grigore Alexandrescu\u2019\u2019, 011743 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5814-2082","authenticated-orcid":false,"given":"Irina","family":"Dijm\u0103rescu","sequence":"additional","affiliation":[{"name":"Departament of Pediatrics and Department of Pediatric Orthopedics, \u201cCarol Davila\u201c University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Departament of Pediatrics and Department of Pediatric Orthopedics, Emergency Hospital for Children \u2018\u2019Grigore Alexandrescu\u2019\u2019, 011743 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirela Lumini\u021ba","family":"Pavelescu","sequence":"additional","affiliation":[{"name":"Departament of Pediatrics and Department of Pediatric Orthopedics, \u201cCarol Davila\u201c University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Departament of Pediatrics and Department of Pediatric Orthopedics, Emergency Hospital for Children \u2018\u2019Grigore Alexandrescu\u2019\u2019, 011743 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8604-8691","authenticated-orcid":false,"given":"Daniela","family":"P\u0103curar","sequence":"additional","affiliation":[{"name":"Departament of Pediatrics and Department of Pediatric Orthopedics, \u201cCarol Davila\u201c University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Departament of Pediatrics and Department of Pediatric Orthopedics, Emergency Hospital for Children \u2018\u2019Grigore Alexandrescu\u2019\u2019, 011743 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1018-1506","authenticated-orcid":false,"given":"Alexandru","family":"Ulici","sequence":"additional","affiliation":[{"name":"Departament of Pediatrics and Department of Pediatric Orthopedics, \u201cCarol Davila\u201c University of Medicine and Pharmacy, 020021 Bucharest, Romania"},{"name":"Departament of Pediatrics and Department of Pediatric Orthopedics, Emergency Hospital for Children \u2018\u2019Grigore Alexandrescu\u2019\u2019, 011743 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0940-9602(02)80023-1","article-title":"Aspects of the History of Osteogenesis Imperfecta (Vrolik\u2019s Syndrome)","volume":"184","author":"Baljet","year":"2002","journal-title":"Ann. Anat.-Anat. Anz."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","article-title":"Osteogenesis Imperfecta","volume":"3","author":"Marini","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Deguchi, M., Tsuji, S., Katsura, D., Kasahara, K., Kimura, F., and Murakami, T. (2021). Current Overview of Osteogenesis Imperfecta. Med. (B Aires), 57.","DOI":"10.3390\/medicina57050464"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","article-title":"Genetic Heterogeneity in Osteogenesis Imperfecta","volume":"16","author":"Sillence","year":"1979","journal-title":"J. Med. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1007\/s10354-015-0361-x","article-title":"Osteogenesis Imperfecta: Pathophysiology and Treatment","volume":"165","author":"Netzer","year":"2015","journal-title":"Wien. Med. Wochenschr."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","article-title":"Osteogenesis Imperfecta","volume":"387","author":"Forlino","year":"2016","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Botor, M., Fus-Kujawa, A., Uroczynska, M., Stepien, K.L., Galicka, A., Gawron, K., and Sieron, A.L. (2021). Osteogenesis Imperfecta: Current and Prospective Therapies. Biomolecules, 11.","DOI":"10.3390\/biom11101493"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/cge.13846","article-title":"The Evolution of the Nosology of Osteogenesis Imperfecta","volume":"99","author":"Chetty","year":"2021","journal-title":"Clin. Genet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jbmr.2410","article-title":"Bisphosphonates for the Prevention of Fractures in Osteogenesis Imperfecta: Meta-Analysis of Placebo-Controlled Trials","volume":"30","author":"Hald","year":"2015","journal-title":"J. Bone Miner. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000381713","article-title":"Efficacy and Safety of Bisphosphonate Therapy in Children with Osteogenesis Imperfecta: A Systematic Review","volume":"84","author":"Rijks","year":"2015","journal-title":"Horm. Res. Paediatr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3389\/fendo.2019.00924","article-title":"Management of Osteogenesis Imperfecta","volume":"10","author":"Ralston","year":"2020","journal-title":"Front Endocrinol"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJM199810013391402","article-title":"Cyclic Administration of Pamidronate in Children with Severe Osteogenesis Imperfecta","volume":"339","author":"Glorieux","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.2147\/DDDT.S141075","article-title":"Therapy with Pamidronate in Children with Osteogenesis Imperfecta","volume":"11","author":"Marginean","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1590\/1678-4685-gmb-2018-0097","article-title":"Cyclic Pamidronate Treatment for Osteogenesis Imperfecta: Report from a Brazilian Reference Center","volume":"42","author":"Pinheiro","year":"2019","journal-title":"Genet. Mol. Biol."},{"key":"ref_15","first-page":"CD005088","article-title":"Bisphosphonate Therapy for Osteogenesis Imperfecta","volume":"2016","author":"Dwan","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Besio, R., and Forlino, A. (2015). New Frontiers for Dominant Osteogenesis Imperfecta Treatment: Gene\/Cellular Therapy Approaches. Adv. Regen. Biol., 2.","DOI":"10.3402\/arb.v2.27964"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10238-012-0218-1","article-title":"Therapeutic Application of Mesenchymal Stem Cells in Bone and Joint Diseases","volume":"14","author":"Liu","year":"2014","journal-title":"Clin. Exp. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"893","DOI":"10.4065\/84.10.893","article-title":"Mesenchymal Stem Cells for Bone Repair and Metabolic Bone Diseases","volume":"84","author":"Undale","year":"2009","journal-title":"Mayo Clin. Proc."},{"key":"ref_19","first-page":"215","article-title":"Mesenchymal Stem Cells: Characteristics and Clinical Applications","volume":"44","author":"Bobis","year":"2006","journal-title":"Folia Histochem. Cytobiol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"39656","DOI":"10.1038\/srep39656","article-title":"Counteracting Bone Fragility with Human Amniotic Mesenchymal Stem Cells","volume":"6","author":"Ranzoni","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1186\/s13287-020-02001-1","article-title":"Mesenchymal Stem Cells: Amazing Remedies for Bone and Cartilage Defects","volume":"11","author":"Kangari","year":"2020","journal-title":"Stem Cell Res. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"101108","DOI":"10.1016\/j.bonr.2021.101108","article-title":"A Systematic Review and Meta-Analysis on the Efficacy of Stem Cell Therapy on Bone Brittleness in Mouse Models of Osteogenesis Imperfecta","volume":"15","author":"Battle","year":"2021","journal-title":"Bone Rep."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41536-019-0083-6","article-title":"Mesenchymal Stem Cell Perspective: Cell Biology to Clinical Progress","volume":"4","author":"Pittenger","year":"2019","journal-title":"NPJ Regen. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s40778-018-0118-8","article-title":"Fetal Mesenchymal Stromal Cells: An Opportunity for Prenatal Cellular Therapy","volume":"4","author":"Sagar","year":"2018","journal-title":"Curr. Stem Cell Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1089\/scd.2013.0132","article-title":"Potential of Human Fetal Chorionic Stem Cells for the Treatment of Osteogenesis Imperfecta","volume":"23","author":"Jones","year":"2014","journal-title":"Stem Cells Dev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1432-0436.2008.00279.x","article-title":"Comparative Osteogenic Transcription Profiling of Various Fetal and Adult Mesenchymal Stem Cell Sources","volume":"76","author":"Guillot","year":"2008","journal-title":"Differentiation"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13619-022-00146-3","article-title":"Mesenchymal Stem Cells in the Treatment of Osteogenesis Imperfecta","volume":"12","author":"Lang","year":"2023","journal-title":"Cell Regen."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s11914-020-00594-3","article-title":"Stem Cell Therapy as a Treatment for Osteogenesis Imperfecta","volume":"18","year":"2020","journal-title":"Curr. Osteoporos. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2217\/17584272.4.1.57","article-title":"Potential Implications of Cell Therapy for Osteogenesis Imperfecta","volume":"4","author":"Niyibizi","year":"2009","journal-title":"Int. J. Clin. Rheumtol"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1182\/blood-2007-08-105809","article-title":"Intrauterine Transplantation of Human Fetal Mesenchymal Stem Cells from First-Trimester Blood Repairs Bone and Reduces Fractures in Osteogenesis Imperfecta Mice","volume":"111","author":"Guillot","year":"2008","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/6529","article-title":"Transplantability and Therapeutic Effects of Bone Marrow-Derived Mesenchymal Cells in Children with Osteogenesis Imperfecta","volume":"5","author":"Horwitz","year":"1999","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1182\/blood.V97.5.1227","article-title":"Clinical Responses to Bone Marrow Transplantation in Children with Severe Osteogenesis Imperfecta","volume":"97","author":"Horwitz","year":"2001","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1002\/ctm2.265","article-title":"Reiterative Infusions of MSCs Improve Pediatric Osteogenesis Imperfecta Eliciting a Pro-osteogenic Paracrine Response: TERCELOI Clinical Trial","volume":"11","author":"Infante","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/01.TP.0000159029.48678.93","article-title":"Fetal Mesenchymal Stem-Cell Engraftment in Bone after In Utero Transplantation in a Patient with Severe Osteogenesis Imperfecta","volume":"79","author":"Hassan","year":"2005","journal-title":"Transplantation"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"255","DOI":"10.5966\/sctm.2013-0090","article-title":"Pre- and Postnatal Transplantation of Fetal Mesenchymal Stem Cells in Osteogenesis Imperfecta: A Two-Center Experience","volume":"3","author":"Westgren","year":"2014","journal-title":"Stem Cells Transl. Med."},{"key":"ref_36","first-page":"28","article-title":"OC09.07: Boost Brittle Bones before Birth (BOOSTB4): A Clinical Trial of Prenatal Stem Cell Transplantation for Treatment of Osteogenesis Imperfecta","volume":"60","author":"Lindgren","year":"2022","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_37","unstructured":"G\u00f6therstr\u00f6m, C. (2023, October 17). Karolinska Institutet Boost Brittle Bones before Birth (BOOSTB4), Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03706482."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"98","DOI":"10.6065\/apem.2346058.029","article-title":"Denosumab Use in Osteogenesis Imperfecta: An Update on Therapeutic Approaches","volume":"28","author":"Majdoub","year":"2023","journal-title":"Ann. Pediatr. Endocrinol. Metab."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","article-title":"Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review","volume":"39","author":"Kendler","year":"2022","journal-title":"Adv. Ther."},{"key":"ref_40","unstructured":"Hildebrand, G.K., and Kasi, A. (2023). StatPearls, StatPearls Publishing."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/ijcp.12022","article-title":"Denosumab: Mechanism of Action and Clinical Outcomes","volume":"66","author":"Hanley","year":"2012","journal-title":"Int. J. Clin. Pr."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1475-2867-9-26","article-title":"Therapeutic Implications of Osteoprotegerin","volume":"9","author":"Fili","year":"2009","journal-title":"Cancer Cell Int."},{"key":"ref_43","first-page":"183","article-title":"First Use of the RANKL Antibody Denosumab in Osteogenesis Imperfecta Type VI","volume":"12","author":"Semler","year":"2012","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3954","DOI":"10.1210\/jc.2014-3072","article-title":"Effect of Denosumab on the Growing Skeleton in Osteogenesis Imperfecta","volume":"99","author":"Semler","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_45","first-page":"24","article-title":"Safety and Efficacy of Denosumab in Children with Osteogenesis Imperfect\u2014A First Prospective Trial","volume":"16","author":"Franklin","year":"2016","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13023-019-1197-z","article-title":"Individualized Treatment with Denosumab in Children with Osteogenesis Imperfecta\u2014Follow up of a Trial Cohort","volume":"14","author":"Rehberg","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s00223-016-0110-1","article-title":"Osteogenesis Imperfecta Type VI in Individuals from Northern Canada","volume":"98","author":"Ward","year":"2016","journal-title":"Calcif. Tissue Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1620\/tjem.242.115","article-title":"Efficacy of Denosumab for Osteoporosis in Three Female Patients with Osteogenesis Imperfecta","volume":"242","author":"Uehara","year":"2017","journal-title":"Tohoku J. Exp. Med."},{"key":"ref_49","first-page":"76","article-title":"Hypercalcemia and Hypercalciuria during Denosumab Treatment in Children with Osteogenesis Imperfecta Type VI","volume":"18","author":"Trejo","year":"2018","journal-title":"J. Musculoskelet. Neuronal Interact."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Kobayashi, T., Nakamura, Y., Suzuki, T., Yamaguchi, T., Takeda, R., Takagi, M., Hasegawa, T., Kosho, T., and Kato, H. (2018). Efficacy and Safety of Denosumab Therapy for Osteogenesis Imperfecta Patients with Osteoporosis\u2014Case Series. J. Clin. Med., 7.","DOI":"10.3390\/jcm7120479"},{"key":"ref_51","first-page":"68","article-title":"Use of Denosumab in Osteogenesis Imperfecta: A Case Report","volume":"26","author":"Maldonado","year":"2019","journal-title":"Rev. Colomb. De Reumatol. (Engl. Ed.)"},{"key":"ref_52","first-page":"470","article-title":"Denosumab in pediatric bone disorders and the role of RANKL blockade: A narrative review","volume":"3","author":"Wang","year":"2012","journal-title":"Transl. Pediatr."},{"key":"ref_53","first-page":"1","article-title":"Sclerostin, an Emerging Therapeutic Target for Treating Osteoporosis and Osteoporotic Fracture: A General Review","volume":"4","author":"Suen","year":"2016","journal-title":"J. Orthop. Transl."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2147\/IJWH.S73244","article-title":"Sclerostin Inhibition: A Novel Therapeutic Approach In the Treatment of Osteoporosis","volume":"7","author":"Lewiecki","year":"2015","journal-title":"Int. J. Womens Health"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/jbmr.3143","article-title":"BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial","volume":"32","author":"Glorieux","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7902046","DOI":"10.1155\/2022\/7902046","article-title":"Serum Sclerostin and Its Association with Bone Turnover Marker in Metabolic Bone Diseases","volume":"2022","author":"Chen","year":"2022","journal-title":"Dis. Markers"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"E920","DOI":"10.1210\/jc.2013-3852","article-title":"Circulating Sclerostin in Children and Young Adults with Heritable Bone Disorders","volume":"99","author":"Palomo","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/jbmr.1717","article-title":"Sclerostin Antibody Improves Skeletal Parameters in a Brtl\/+ Mouse Model of Osteogenesis Imperfecta","volume":"28","author":"Sinder","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/jbmr.2198","article-title":"Targeting the LRP5 Pathway Improves Bone Properties in a Mouse Model of Osteogenesis Imperfecta","volume":"29","author":"Jacobsen","year":"2014","journal-title":"J. Bone Miner. Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s00198-014-2737-y","article-title":"Adult Brtl\/+ Mouse Model of Osteogenesis Imperfecta Demonstrates Anabolic Response to Sclerostin Antibody Treatment with Increased Bone Mass and Strength","volume":"25","author":"Sinder","year":"2014","journal-title":"Osteoporos. Int."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.bone.2014.06.015","article-title":"Effect of Sclerostin Antibody Treatment in a Mouse Model of Severe Osteogenesis Imperfecta","volume":"66","author":"Roschger","year":"2014","journal-title":"Bone"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.bone.2014.10.012","article-title":"Rapidly Growing Brtl\/+ Mouse Model of Osteogenesis Imperfecta Improves Bone Mass and Strength with Sclerostin Antibody Treatment","volume":"71","author":"Sinder","year":"2015","journal-title":"Bone"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2016.01.001","article-title":"Effect of Anti-Sclerostin Therapy and Osteogenesis Imperfecta on Tissue-Level Properties in Growing and Adult Mice While Controlling for Tissue Age","volume":"84","author":"Sinder","year":"2016","journal-title":"Bone"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/jbmr.2776","article-title":"Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap \u2212\/\u2212 Mice, a Model of Recessive Osteogenesis Imperfecta","volume":"31","author":"Grafe","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bone.2019.04.011","article-title":"Sclerostin Antibody Reduces Long Bone Fractures in the Oim\/Oim Model of Osteogenesis Imperfecta","volume":"124","author":"Cardinal","year":"2019","journal-title":"Bone"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"5645","DOI":"10.7150\/thno.63177","article-title":"Therapeutic Aptamer Targeting Sclerostin Loop3 for Promoting Bone Formation without Increasing Cardiovascular Risk in Osteogenesis Imperfecta Mice","volume":"12","author":"Wang","year":"2022","journal-title":"Theranostics"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/mrcr\/rxab018","article-title":"Efficacy of Romosozumab for Osteoporosis in a Patient with Osteogenesis Imperfecta: A Case Report","volume":"6","author":"Uehara","year":"2022","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.aace.2023.10.002","article-title":"Osteoporosis Improved by Romosozumab Therapy in a Patient With Type I Osteogenesis Imperfecta","volume":"9","author":"Dattagupta","year":"2023","journal-title":"AACE Clin. Case Rep."},{"key":"ref_69","unstructured":"Vall, H., and Pamar, M. (2023). Teriparatide, StatPearls Publishing."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Hauser, B., Alonso, N., and Riches, P.L. (2021). Review of Current Real-World Experience with Teriparatide as Treatment of Osteoporosis in Different Patient Groups. J. Clin. Med., 10.","DOI":"10.3390\/jcm10071403"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1172\/JCI71101","article-title":"Evaluation of Teriparatide Treatment in Adults with Osteogenesis Imperfecta","volume":"124","author":"Orwoll","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"153","DOI":"10.11138\/ccmbm\/2017.14.1.153","article-title":"Efficacy of Teriparatide vs Neridronate in Adults with Osteogenesis Imperfecta Type I: A Prospective Randomized International Clinical Study","volume":"14","author":"Leali","year":"2017","journal-title":"Clin. Cases Miner. Bone Metab."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e078164","DOI":"10.1136\/bmjopen-2023-078164","article-title":"Protocol of a Randomised Trial of Teriparatide Followed by Zoledronic Acid to Reduce Fracture Risk in Adults with Osteogenesis Imperfecta","volume":"13","author":"Hald","year":"2023","journal-title":"BMJ Open"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nm.3544","article-title":"Excessive Transforming Growth Factor-\u03b2 Signaling Is a Common Mechanism in Osteogenesis Imperfecta","volume":"20","author":"Grafe","year":"2014","journal-title":"Nat. Med."},{"key":"ref_75","first-page":"3505","article-title":"TGF-\u03b21 Promotes the Osteoinduction of Human Osteoblasts via the PI3K\/AKT\/MTOR\/S6K1 Signalling Pathway","volume":"19","author":"Zhang","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"16009","DOI":"10.1038\/boneres.2016.9","article-title":"TGF-\u03b2 and BMP Signaling in Osteoblast, Skeletal Development, and Bone Formation, Homeostasis and Disease","volume":"4","author":"Wu","year":"2016","journal-title":"Bone Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e152571","DOI":"10.1172\/JCI152571","article-title":"Targeting TGF-\u03b2 for Treatment of Osteogenesis Imperfecta","volume":"132","author":"Song","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000328133","article-title":"Allele-Specific Gene Silencing in Osteogenesis Imperfecta","volume":"21","author":"Ljunggren","year":"2011","journal-title":"Endocr. Dev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/ejhg.2013.198","article-title":"Allele-Specific Col1a1 Silencing Reduces Mutant Collagen in Fibroblasts from Brtl Mouse, a Model for Classical Osteogenesis Imperfecta","volume":"22","author":"Rousseau","year":"2014","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/jbmr.4549","article-title":"Curative Cell and Gene Therapy for Osteogenesis Imperfecta","volume":"37","author":"Schindeler","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1172\/JCI118434","article-title":"Antisense Oligodeoxynucleotides Selectively Suppress Expression of the Mutant Alpha 2(I) Collagen Allele in Type IV Osteogenesis Imperfecta Fibroblasts. A Molecular Approach to Therapeutics of Dominant Negative Disorders","volume":"97","author":"Wang","year":"1996","journal-title":"J. Clin. Investig."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/sj.ejhg.5201230","article-title":"RNAi of COL1A1 in Mesenchymal Progenitor Cells","volume":"12","author":"McMahon","year":"2004","journal-title":"Eur. J. Hum. Genet."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1126\/science.1088757","article-title":"Gene Targeting in Stem Cells from Individuals with Osteogenesis Imperfecta","volume":"303","author":"Chamberlain","year":"2004","journal-title":"Science"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/sj.mt.6300339","article-title":"Gene Targeting of Mutant COL1A2 Alleles in Mesenchymal Stem Cells From Individuals With Osteogenesis Imperfecta","volume":"16","author":"Chamberlain","year":"2008","journal-title":"Mol. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.7150\/ijms.5774","article-title":"Allele Dependent Silencing of Collagen Type I Using Small Interfering RNAs Targeting 3\u2032UTR Indels\u2014A Novel Therapeutic Approach in Osteogenesis Imperfecta","volume":"10","author":"Lindahl","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"361","DOI":"10.7150\/ijms.5.361","article-title":"Allele Dependent Silencing of COL1A2 Using Small Interfering RNAs","volume":"5","author":"Lindahl","year":"2008","journal-title":"Int. J. Med. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.biocel.2015.01.015","article-title":"The Therapeutic Effects of 4-Phenylbutyric Acid in Maintaining Proteostasis","volume":"61","author":"Kolb","year":"2015","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Takeyari, S., Kubota, T., Ohata, Y., Fujiwara, M., Kitaoka, T., Taga, Y., Mizuno, K., and Ozono, K. (2021). 4-Phenylbutyric Acid Enhances the Mineralization of Osteogenesis Imperfecta IPSC-Derived Osteoblasts. J. Biol. Chem., 296.","DOI":"10.1074\/jbc.RA120.014709"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1093\/hmg\/ddx171","article-title":"The Chaperone Activity of 4PBA Ameliorates the Skeletal Phenotype of Chihuahua, a Zebrafish Model for Dominant Osteogenesis Imperfecta","volume":"26","author":"Gioia","year":"2017","journal-title":"Hum. Mol. Genet."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/jbmr.4501","article-title":"4-PBA Treatment Improves Bone Phenotypes in the Aga2 Mouse Model of Osteogenesis Imperfecta","volume":"37","author":"Duran","year":"2022","journal-title":"J. Bone Miner. Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e149636","DOI":"10.1172\/jci.insight.149636","article-title":"4PBA Reduces Growth Deficiency in Osteogenesis Imperfecta by Enhancing Transition of Hypertrophic Chondrocytes to Osteoblasts","volume":"7","author":"Scheiber","year":"2022","journal-title":"JCI Insight"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.matbio.2023.06.003","article-title":"Cell Differentiation and Matrix Organization Are Differentially Affected during Bone Formation in Osteogenesis Imperfecta Zebrafish Models with Different Genetic Defects Impacting Collagen Type I Structure","volume":"121","author":"Daponte","year":"2023","journal-title":"Matrix Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1016\/j.bbadis.2018.02.002","article-title":"4-PBA Ameliorates Cellular Homeostasis in Fibroblasts from Osteogenesis Imperfecta Patients by Enhancing Autophagy and Stimulating Protein Secretion","volume":"1864","author":"Besio","year":"2018","journal-title":"Biochim. Et. Biophys. Acta (BBA)-Mol. Basis Dis."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Takeyari, S., Ohata, Y., Kubota, T., Taga, Y., Mizuno, K., and Ozono, K. (2019). Analysis of Osteogenesis Imperfecta in Pathology and the Effects of 4-Phenylbutyric Acid Using Patient-Derived Fibroblasts and Induced Pluripotent Stem Cells. Bone Abstr., 7.","DOI":"10.1530\/boneabs.7.OC13"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"233","DOI":"10.11005\/jbm.2014.21.4.233","article-title":"Regulation of NFATc1 in Osteoclast Differentiation","volume":"21","author":"Kim","year":"2014","journal-title":"J. Bone Metab."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.cellsig.2012.11.015","article-title":"Osteoporosis Regulation by Salubrinal through EIF2\u03b1 Mediated Differentiation of Osteoclast and Osteoblast","volume":"25","author":"He","year":"2013","journal-title":"Cell Signal."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.cellsig.2014.11.020","article-title":"In Vitro and in Silico Analysis of an Inhibitory Mechanism of Osteoclastogenesis by Salubrinal and Guanabenz","volume":"27","author":"Hamamura","year":"2015","journal-title":"Cell Signal."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jphs.2016.09.006","article-title":"Salubrinal Improves Mechanical Properties of the Femur in Osteogenesis Imperfecta Mice","volume":"132","author":"Takigawa","year":"2016","journal-title":"J. Pharmacol. Sci."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/4\/1065\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:59:24Z","timestamp":1760104764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/4\/1065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,13]]},"references-count":98,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["jcm13041065"],"URL":"https:\/\/doi.org\/10.3390\/jcm13041065","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,13]]}}}